These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1580304)

  • 1. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): a case report.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Tremblay M; Labrie F
    Am J Med; 1992 May; 92(5):563-6. PubMed ID: 1580304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of liver toxicity associated with the use of flutamide in prostate cancer patients.
    Gomez JL; Dupont A; Cusan L; Tremblay M; Suburu R; Lemay M; Labrie F
    Am J Med; 1992 May; 92(5):465-70. PubMed ID: 1349790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Fatal fulminant hepatitis induced by nilutamide (Anandron)].
    Pescatore P; Hammel P; Durand F; Bertheau P; Bernuau J; Huc D; Gerbal JL; Degott C; Benhamou JP
    Gastroenterol Clin Biol; 1993; 17(6-7):499-501. PubMed ID: 8243938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary complications of hormone treatment in prostate carcinoma.
    Seigneur J; Trechot PF; Hubert J; Lamy P
    Chest; 1988 May; 93(5):1106. PubMed ID: 3129240
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Cusan L; Raynaud JP; Husson JM; Fazekas AT
    Horm Res; 1983; 18(1-3):18-27. PubMed ID: 6411578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interstitial pneumonitis associated with neoadjuvant leuprolide and nilutamide for prostate cancer.
    Wieder JA; Soloway MS
    J Urol; 1998 Jun; 159(6):2099. PubMed ID: 9598539
    [No Abstract]   [Full Text] [Related]  

  • 7. Total androgen blockade with the use of orchiectomy and nilutamide (Anandron) or placebo as treatment of metastatic prostate cancer. Anandron International Study Group.
    Janknegt RA
    Cancer; 1993 Dec; 72(12 Suppl):3874-7. PubMed ID: 8252507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anandron (RU 23908) in metastatic prostate cancer: preliminary results of a multicentric Italian study.
    Boccardo F; Decensi AU; Guarneri D; Martorana G; Fioretto L; Mini E; Macaluso MP; Giuliani L; Santi L; Periti P
    Cancer Detect Prev; 1991; 15(6):501-3. PubMed ID: 1782640
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocular toxicity of Anandron in patients treated for prostatic cancer.
    Harnois C; Malenfant M; Dupont A; Labrie F
    Br J Ophthalmol; 1986 Jun; 70(6):471-3. PubMed ID: 3718913
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nilutamide pneumonitis: a report on eight patients.
    Pfitzenmeyer P; Foucher P; Piard F; Coudert B; Braud ML; Gabez P; Lacroix S; Mabille JP; Camus P
    Thorax; 1992 Aug; 47(8):622-7. PubMed ID: 1412120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma.
    Faure N; Lemay A; Laroche B; Robert G; Plante R; Jean C; Thabet M; Roy R; Fazekas AT
    Prostate; 1983; 4(6):601-24. PubMed ID: 6415632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pure antiandrogen RU 23908 (Anandron), a candidate of choice for the combined antihormonal treatment of prostatic cancer: a review.
    Raynaud JP; Bonne C; Moguilewsky M; Lefebvre FA; Bélanger A; Labrie F
    Prostate; 1984; 5(3):299-311. PubMed ID: 6374639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer.
    Labrie F; Dupont A; Bélanger A; Emond J; Monfette G
    Proc Natl Acad Sci U S A; 1984 Jun; 81(12):3861-3. PubMed ID: 6427777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [New approach in the treatment of prostatic cancer: combined use of a LHRH agonist and an androgen antagonist].
    Labrie F; Dupont A; Belanger A; Lefebvre FA; Raynaud JP
    J Pharmacol; 1983; 14 Suppl 3():117-35. PubMed ID: 6423907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pulmonary toxicity of nilutamide (Anandron). Cooperative evaluation of French Regional Pharmacovigilance Centers].
    Jonville AP; Diot E; Dutertre JP; Autret E
    Therapie; 1992; 47(5):393-7. PubMed ID: 1299978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide).
    Kuhn JM; Billebaud T; Navratil H; Moulonguet A; Fiet J; Grise P; Louis JF; Costa P; Husson JM; Dahan R
    N Engl J Med; 1989 Aug; 321(7):413-8. PubMed ID: 2503723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.
    Labrie F; Dupont A; Belanger A; Cusan L; Lacourciere Y; Monfette G; Laberge JG; Emond JP; Fazekas AT; Raynaud JP; Husson JM
    Clin Invest Med; 1982; 5(4):267-75. PubMed ID: 6819101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of the nonsteroidal antiandrogen nilutamide on adrenal androgen secretion.
    Decensi A; Torrisi R; Marroni P; Pensa F; Padovani P; Boccardo F
    Prostate; 1994; 24(1):17-23. PubMed ID: 8290386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term endocrine effects of administration of either a non-steroidal antiandrogen or a luteinizing hormone-releasing hormone agonist in men with prostate cancer.
    Decensi A; Torrisi R; Fontana V; Marroni P; Padovani P; Guarneri D; Minuto F; Boccardo F
    Acta Endocrinol (Copenh); 1993 Oct; 129(4):315-21. PubMed ID: 8237249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multivariate analysis of plasma hormones in patients with metastatic prostate cancer receiving combined LHRH-analog and antiandrogen therapy.
    Fiet J; Doré JC; Gô AL; Ojasoo T; Raynaud JP
    Prostate; 1993; 23(4):291-313. PubMed ID: 8259343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.